{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-007410","form_type":"8-K","ticker":"CHRS","cik":"0001512762","company_name":"Coherus Oncology, Inc.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.550990+00:00","generated_at":"2026-05-21T23:32:51.227248+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Coherus Q1 2025: LOQTORZI rev $7.3M, net loss $47.4M; UDENYCA divestiture closed","bullets":["Continuing ops net loss $47.4M ($0.41 diluted); non-GAAP net loss $40.9M ($0.35).","LOQTORZI net revenue $7.3M, patient demand grew >15% vs Q4 2024.","UDENYCA divestiture closed April 2025 for upfront $483.4M, total up to $558.4M.","CHS-114 Phase 1b shows confirmed partial response in PD-1 refractory HNSCC; proof of mechanism.","Casdozokitug Phase 2 randomized trial in 1L HCC enrolling; data readout expected 1H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-007410","json":"https://secwatch.observer/filing/0001558370-25-007410.json","markdown":"https://secwatch.observer/filing/0001558370-25-007410.md","text":"https://secwatch.observer/filing/0001558370-25-007410.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1512762/000155837025007410/0001558370-25-007410-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1512762/000155837025007410/chrs-20250512x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T23:32:51.227248+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}